New Gene Therapies Could Change Hemophilia Forever
At last week's American Society of Hemophilia conference, Spark Therapeutics (NASDAQ: ONCE) and BioMarin (NASDAQ: BMRN) presented promising data for gene therapy drugs that could change the way hemophilia is treated, making patients' lives significantly easier and safer.
In this clip from Industry Focus: Healthcare, analysts explain how the drugs work and why they're so exciting, how the gene therapy differs from the current standard of care, the difference between Spark's SPD-8011 and BioMarin's BMN 270, which company investors might want to take a closer look at, why Spark's share price fell after the company reported encouraging data at the conference, and more.
A full transcript follows the video.
Source: Fool.com
Pfizer Inc. Aktie
26,00 €
1,31 %
Die Pfizer Inc. Aktie zieht viel Aufmerksamkeit auf sich: Viel mehr Buy- als Sell-Einschätzungen.
Das Kursziel von 41 € für Pfizer Inc. weist auf eine Steigerung von über 50% gegenüber dem aktuellen Kurs von 26.0 € hin.
